九州通：通过大模型赋能研发，大幅减少技术开发时间，带来约38%的效率提升

Group 1 - The company is actively embracing AI technology through self-research and partnerships with leading firms like Alibaba Cloud and Tencent Cloud, developing AI applications for various scenarios to accelerate digital transformation in business and management [1][2] - AI applications include smart logistics, integrated Chinese and Western medicine diagnosis, medical devices, and intelligent office solutions, significantly improving operational efficiency and patient experience across different platforms [1][2] - The AI logistics project "Goods to Person" has enhanced overall efficiency by 10% through the application of intelligent scheduling algorithms across the entire lifecycle of order grouping, product storage, and dispatch [1] Group 2 - The company has implemented an internal office system and a digital assistant "Zhi Jiu Ge" integrated with DeepSeek, resulting in a 38% increase in work efficiency [2] - As of July 2025, the company has over 2,400 clinic membership stores and aims to establish a network of 10,000 clinics within three years, focusing on a business model that integrates medical services with supply chain management [2] - The company has introduced over 260 new products in the first half of the year, enhancing the product structure in clinics through partnerships with various upstream manufacturers [2] Group 3 - The company has launched the "Jiu Yi SaaS Clinic Manager" system, enabling rapid operations such as 3-second record creation and 10-second prescription issuance, with 1,525 clinic membership stores currently using the system [3] - The AI-assisted diagnosis platform developed in collaboration with Tencent Cloud covers nearly 3,000 diseases and over 110,000 drug knowledge, with an average of 51,000 uses per month across member stores [3] - The new product strategy, as part of the "Three New and Two Transformations" strategy, is crucial for future development, focusing on integrating resources across the group to introduce clinically valuable and marketable new products [3] Group 4 - The company has established a new product strategy fund, "Wuhan Jiu Ying Venture Capital Fund Partnership," with a scale of 500 million yuan, focusing on innovative drugs and high-end generics [4]